news
New migraine research backs gepants, CGRP antibodies, neuromodulation
New Danish research identifies the top three treatments for severe migraine: CGRP antibodies, gepants, and neuromodulation devices. These options target specific mechanisms in the nervous system to prevent and alleviate pain, offering alternatives beyond traditional painkillers. It's for anyone managing chronic migraine.
New Danish research identifies the top three treatments for severe migraine: CGRP antibodies, gepants, and neuromodulation devices. These options target specific mechanisms in the nervous system to prevent and alleviate pain, offering alternatives beyond traditional painkillers. It's for anyone managing chronic migraine.
The architecture take
The new research out of Denmark isn't just another rehash; it confirms what many specialists already know: migraine isn't just a bad headache, and treating it needs more than ibuprofen. They're pointing to CGRP antibodies and gepants, which actually block the calcitonin gene-related peptide — a key player in migraine pain signaling. Think of it as shutting down the inflammatory response before it even starts, not just sweeping up the mess afterward. Neuromodulation devices also made the cut, suggesting we're finally moving beyond a one-size-fits-all pill approach. This means real relief for people who previously had few options, moving care from just symptom management to prevention. I've seen too many people stuck in cycles of pain, and this kind of targeted therapy, focusing on specific nervous system pathways, is how we shift the baseline. The next step is getting these treatments to more people, faster.